%0 Journal Article
%T Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
%J -
%D 2018
%R https://doi.org/10.1038/s41416-018-0318-0
%X Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab
%U https://www.nature.com/articles/s41416-018-0318-0